Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · October 19, 2017

Extended Adjuvant Aromatase Inhibition After Sequential Endocrine Therapy

The Lancet Oncology

 

Additional Info

The Lancet Oncology
Extended Adjuvant Aromatase Inhibition After Sequential Endocrine Therapy (DATA): A Randomised, Phase 3 Trial
Lancet Oncol 2017 Oct 11;[EPub Ahead of Print], VCG Tjan-Heijnen, IEG van Hellemond, PGM Peer, ACP Swinkels, CH Smorenburg, MJC van der Sangen, JR Kroep, H De Graaf, AH Honkoop, FLG Erdkamp, FWPJ van den Berkmortel, M de Boer, WK de Roos, SC Linn, ALT Imholz, CM Seynaeve

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading